|
|
|
|
|
|
By Steve Fawell, AstraZeneca | As we continue to discover new treatment approaches, we need to go beyond targeting proteins with well-defined pockets and find other ways to target the undruggable. Two approaches that show promise are PROTACs and molecular glues. |
|
|
|
|
| Developing Biosimilars: Challenges And Solutions | Infographic | Sartorius | The technologies used for biophysical characterization often require expensive reagents, large sample quantities, and optimization for experimental conditions. Simplified analytical workflows can help. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|